ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today provided a financial and pipeline update for the second quarter ended June 30, 2015. “The growth of AMPYRA over the last several quarters is a result of our team’s continued strong performance in educating healthcare professionals and people with MS about the value of this important medication,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “Our top priority is successful development of our clinical pi